Avero Diagnostics AMBLor

Avero Diagnostics has launched the AMBLor test for identifying early-stage melanomas at low risk of progression. The test is being launched in the US first, though it has been available as a referral service in the UK since July, a company spokesperson said. Avero licensed the underlying technology for the test from AMLo Biosciences. It identifies the presence of AMBRA1 and loricrin, two prognostic protein biomarkers, in the skin underlying the tumor. The absence of the biomarkers in early-stage melanoma is associated with tumors at normal or high risk of progression, Avero said, while normal expression of one or both biomarkers is associated with low risk of progression.